Explore the vast range of titles available.

Hereditary transthyretin amyloidosis is caused by the deposition of misfolded transthyretin proteins in peripheral nerves and other tissues. This phase 3 trial tested patisiran, a small interfering RNA targeting transthyretin messenger RNA, to treat the disease.

Gait assessment is key in Parkinson’s disease (PD), but the psychometric properties of common tests like the 6-Minute Walk Test (6MWT) are not fully established. Inertial Measurement Units (IMUs) offer objective gait measures, potentially reducing repeated testing. This study evaluated whether the resampling of the first 2 min of the 6MWT (2’6MWT) reflects full-test performance in 43 early-to-mild PD patients (median age 65) at baseline, 1-year, and 2-year follow-ups. A trunk-mounted IMU recorded distance covered, walking duration, stride length, gait speed, cadence, and symmetry. Analysis focused on participants with complete longitudinal data from a multicenter original cohort of 62. Stride length and gait speed (2’6MWT vs. 6MWT) demonstrated strong correlations (r > 0.98), near-perfect agreement, <5% error, and stability across follow-ups; cadence showed slightly more variability. The analysis of consecutive 2-min intervals of the 6MWT revealed stable stride length and gait speed, with modest decreases in distance and cadence over time. Exploratory associations of 2’6MWT and 6MWT with motor severity and cognitive status were consistent. These results indicate the 2’6MWT is a reliable, time-efficient alternative to the full 6MWT for assessing walking capacity in PD, especially in outpatient or fatigue-prone patients. The full 6MWT remains valuable for detecting subtle endurance- or fatigue-related changes.

The 6-minute-walk distance (6MWD) test predicts mortality in chronic obstructive pulmonary disease (COPD). Whether variability in study type (observational vs. interventional) or region performed limits use of the test as a stratification tool or outcome measure for therapeutic trials is unclear. To analyze the original data from several large observational studies and from randomized clinical trials with bronchodilators to support the qualification of the 6MWD test as a drug development tool in COPD. Original data from 14,497 patients with COPD from six observational (n = 9,641) and five interventional (n = 4,856) studies larger than 100 patients and longer than 6 months in duration were included. The geographical, anthropometrics, FEV , dyspnea, comorbidities, and health status scores were measured. Associations between 6MWD and mortality, hospitalizations, and exacerbations adjusted by study type, age, and sex were evaluated. Thresholds for outcome prediction were calculated using receiver operating curves. The change in 6MWD after inhaled bronchodilator treatment and surgical lung volume reduction were analyzed to evaluate the responsiveness of the test as an outcome measure. The 6MWD was significantly lower in nonsurvivors, those hospitalized, or who exacerbated compared with those without events at 6, 12, and greater than 12 months. At these time points, the 6MWD receiver operating characteristic curve-area under the curve to predict mortality was 0.71, 0.70, and 0.68 and for hospitalizations was 0.61, 0.60, and 0.59, respectively. After treatment, the 6MWD was not different between placebo and bronchodilators but increased after surgical lung volume reduction compared with medical therapy. Variation across study types (observational or therapeutic) or regions did not confound the ability of 6MWD to predict outcome. The 6MWD test can be used to stratify patients with COPD for clinical trials and interventions aimed at modifying exacerbations, hospitalizations, or death.

ABSTRACT The 6‐min walk test (6MWT) has significant prognostic value, but requires long walking distances and lacks evaluation of exercise speed. This study aimed to investigate the clinical utility of a new walk test, the 18‐meter walk test (18MWT), in patients with pulmonary arterial hypertension (PAH) as a complement to the 6MWT. In summary, a total of 117 patients with PAH from January 2018 to December 2022 were included. Spearman correlation, Cox regression, and Kaplan–Meier analysis were utilized to demonstrate the value of 18MWT in predicting disease severity and clinical worsening. The median time to complete the 18MWT was 12.8 s (interquartile range: 11.3–14.6 s). 18MWT completion time showed significant correlations with indicators such as N‐terminal pro‐brain natriuretic peptide and 6MWT distance. Adjusted Cox regression showed 18MWT time remained an independent predictor of clinical worsening (hazard ratio = 1.10; 95% confidence interval: 1.01–1.21; p = 0.026). A simplified risk stratification using WHO functional class, 6MWT distance, 18MWT time and NT‐proBNP was predictive of 1‐year clinical outcome. These results suggest that the 18MWT provides clinicians with an efficient measure that can be used to evaluate the disease severity of PAH patients and to identify those patients at greater risk for future clinical worsening as a complement to the 6MWT.

The 1-minute sit-to-stand (STS) test could be valuable to assess the level of exercise tolerance in chronic obstructive pulmonary disease (COPD). There is a need to provide the minimal important difference (MID) of this test in pulmonary rehabilitation (PR). COPD patients undergoing the 1-minute STS test before PR were included. The test was performed at baseline and the end of PR, as well as the 6-minute walk test, and the quadriceps maximum voluntary contraction (QMVC). Home and community-based programs were conducted as recommended. Responsiveness to PR was determined by the difference in the 1-minute STS test between baseline and the end of PR. The MID was evaluated using distribution and anchor-based methods. Forty-eight COPD patients were included. At baseline, the significant predictors of the number of 1-minute STS repetitions were the 6-minute walk distance (6MWD) ( =0.574; <10 ), age ( =-0.453; =0.001), being on long-term oxygen treatment ( =-0.454; =0.017), and the QMVC ( =0.424; =0.031). The multivariate analysis explained 75.8% of the variance of 1-minute STS repetitions. The improvement of the 1-minute STS repetitions at the end of PR was 3.8±4.2 ( <10 ). It was mainly correlated with the change in QMVC ( =0.572; =0.004) and 6MWD ( =0.428; =0.006). Using the distribution-based analysis, an MID of 1.9 (standard error of measurement method) or 3.1 (standard deviation method) was found. With the 6MWD as anchor, the receiver operating characteristic curve identified the MID for the change in 1-minute STS repetitions at 2.5 (sensibility: 80%, specificity: 60%) with area under curve of 0.716. The 1-minute STS test is simple and sensitive to measure the efficiency of PR. An improvement of at least three repetitions is consistent with physical benefits after PR.

Wearable sensors are becoming increasingly popular for complementing classical clinical assessments of gait deficits. The aim of this review is to examine the existing knowledge by systematically reviewing a large number of papers focusing on the use of wearable inertial sensors for the assessment of gait during the 6-minute walk test (6MWT), a widely recognized, simple, non-invasive, low-cost and reproducible exercise test. After a systematic search on PubMed and Scopus databases, two raters evaluated the quality of 28 full-text articles. Then, the available knowledge was summarized regarding study design, subjects enrolled (number of patients and pathological condition, if any, age, male/female ratio), sensor characteristics (type, number, sampling frequency, range) and body placement, 6MWT protocol and extracted parameters. Results were critically discussed to suggest future directions for the use of inertial sensor devices in the clinics.

The 6-minute walk test (6MWT) measures exercise capacity in cardiorespiratory, neurological, and musculoskeletal conditions. It consists of observing how far a patient can walk in 6 minutes and is usually performed in a corridor in a clinic. During the COVID-19 pandemic, as health care systems cancelled nonurgent outpatient appointments, many tests were conducted online. At Oxford University Hospitals National Health Service Foundation Trust, patients followed up on by cardiovascular outpatient clinics were asked to use the open-source Timed Walk app to perform the 6MWT in their community as a substitute for the regular tests in the clinic. This study aimed to assess the clinical usefulness of the app within the context of the pandemic. Consented patients were invited to perform a 6MWT outdoors using the app at least once a month and report the results through periodic telephone calls and visits. Clinical decisions made for the same cohort were registered, with a focus on the effect of the app in supporting decision-making. Data collected through the app during the study period were compared with 6MWTs performed in the prepandemic period. This study was conducted between October 2021 and December 2022. A total of 55 participants consented (n=25, 45% female; mean age 44.80, SD 17.49 y). In total, 741 events were logged. A total of 51 medical decisions were made for 25 patients; in 41% (21/51) of the decisions, the app played a role, affecting 44% (11/25) of the patients. Between 2018 and 2022, a cohort of 49 patients for whom data were available performed 63 6MWTs in the clinic (18 in 2021), whereas the same patients performed 605 tests using the app in 2022 (ie, October 2021 to December 2022). The use of the Timed Walk app for remote 6MWTs allowed clinicians to obtain frequent and objective indications of the status of the patients during the pandemic, compensating for the absence of regular clinic appointments and providing 33 times more tests than in the prepandemic period. These tests supported approximately half of the clinical decisions made regarding the consented patients, showing that the app is useful in clinical practice.

Background: Current guidelines for the treatment of noncystic fibrosis bronchiectasis (NCFB) recommend pulmonary rehabilitation (PR), but to date, there are few studies that have proven its effectiveness. Objective: The main objective of this study was to examine the effect of PR on pulmonary function tests and exercise capacity. Method: The aim of this study was to systematically review the effects of PR in NCFB on (1) forced expiratory volume in the first second (FEV 1 ) and (2) exercise capacity evaluated by the 6-min walk test (6MWT) and the incremental shuttle walk test (ISWT). This meta-analysis was undertaken according to PRISMA recommendations. Results: This pair-wise meta-analysis included data obtained from studies that enrolled 529 NCFB patients. The FEV 1 assessment after PR between the active and control group did not show any significant increase (FEV 1 difference 0.084 mL; CI: −0.064, +0.233; p = 0.264), and there was an increasing trend (188 mL; CI: −0 to 0.009, +0.384) at the limits of statistical significance (p = 0.061). Walked distance showed a significant increase in the PR group compared to the control group (ISWT distance difference 070.0 m; CI: 55.2, 84.8; p < 0.001), and this finding was confirmed before and after PR both by the ISWT (68.85 m greater than baseline; CI: 40.52, 97.18; p < 0.001) and by the 6MWT (37.7 m greater than baseline; CI: 20.22, 55.25; p < 0.001). Conclusions: PR improves exercise tolerance in NCFB patients, but it has a modest impact on respiratory function.

Affective responses during physical activity (PA) are important for engagement in PA programs and for adherence to a physically active lifestyle. Little is known about the affective responses to PA bouts lasting longer than 45 minutes. Therefore, the aims of the present study were to analyse acute effects on affective responses of a three-hour outdoor PA intervention (mountain hiking) compared to a sedentary control situation and to an indoor treadmill condition. Using a randomized crossover design, 42 healthy participants were randomly exposed to three different conditions: outdoor mountain hiking, indoor treadmill walking, and sedentary control situation (approximately three hours each). Measures included the Feeling Scale, Felt Arousal Scale and a Mood Survey Scale. Repeated measures ANOVAs were used to analyse differences between the conditions. Compared to the control situation, the participants showed a significant increase in affective valence (d = 1.21, p < .001), activation (d = 0.81, p = .004), elation (d = 1.07, p < .001), and calmness (d = 0.84, p = .004), and a significant decrease in fatigue (d = -1.19, p < .001) and anxiety (d = -.79, p < .001) after mountain hiking. Outdoor mountain hiking showed significantly greater positive effects on affective valence, activation, and fatigue compared to indoor treadmill walking. The results indicate that a three-hour PA intervention (mountain hiking) elicits higher positive and lower negative affective responses compared to a sedentary control situation and to an indoor PA condition. Outdoor mountain hiking can be recommended by health professionals as a form of PA with the potential to positively influence affective responses. ClinicalTrials.gov NCT02853760. https://clinicaltrials.gov/. Date of registration: 08/02/2016 (retrospectively registered). Date of enrolment of the first participant to the trial: 05/01/2014.

In the pandemic time, the monitoring of the progression of some diseases is affected and rehabilitation is more complicated. Remote monitoring may help solve this problem using mobile devices that embed low-cost sensors, which can help measure different physical parameters. Many tests can be applied remotely, one of which is the six-minute walk test (6MWT). The 6MWT is a sub-maximal exercise test that assesses aerobic capacity and endurance, allowing early detection of emerging medical conditions with changes. This paper presents a systematic review of the use of sensors to measure the different physical parameters during the performance of 6MWT, focusing on various diseases, sensors, and implemented methodologies. It was performed with the PRISMA methodology, where the search was conducted in different databases, including IEEE Xplore, ACM Digital Library, ScienceDirect, and PubMed Central. After filtering the papers related to 6MWT and sensors, we selected 31 papers that were analyzed in more detail. Our analysis discovered that the measurements of 6MWT are primarily performed with inertial and magnetic sensors. Likewise, most research studies related to this test focus on multiple sclerosis and pulmonary diseases.